GSK's Arexvy RSV Vaccine Approved by EU for All Adults

GSK plc (GSK) announced on January 26, 2026, that its Arexvy respiratory syncytial virus (RSV) vaccine has received European Commission approval for use in adults aged 18 and older. The decision expands the vaccine's label from its initial authorization for adults 60 and over. The approval is based on positive Phase III trial data. Arexvy is the first RSV vaccine approved in the EU for the broader adult population, potentially expanding GSK's market reach significantly. The company's shares were active following the regulatory news.